Key Insights

Highlights

Success Rate

82% trial completion

Published Results

20 trials with published results (20%)

Research Maturity

61 completed trials (62% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

13.1%

13 terminated out of 99 trials

Success Rate

82.4%

-4.1% vs benchmark

Late-Stage Pipeline

23%

23 trials in Phase 3/4

Results Transparency

33%

20 of 61 completed with results

Key Signals

20 with results82% success13 terminated

Data Visualizations

Phase Distribution

77Total
Not Applicable (11)
P 1 (17)
P 2 (26)
P 3 (15)
P 4 (8)

Trial Status

Completed61
Terminated13
Unknown12
Withdrawn5
Not Yet Recruiting3
Recruiting3

Trial Success Rate

82.4%

Benchmark: 86.5%

Based on 61 completed trials

Clinical Trials (99)

Showing 20 of 20 trials
NCT07440225Phase 2Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

NCT07496567Phase 2Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

NCT04704921Phase 2Active Not Recruiting

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

NCT07187804Phase 4Not Yet Recruiting

Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization

NCT07002372Not ApplicableRecruiting

Effect of Video Viewing on Intravitreal Injection Experience

NCT04439708Active Not RecruitingPrimary

Biomarkers and Choroidal Neovascularization

NCT06918028Not Yet Recruiting

An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings

NCT02307682Phase 3Completed

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

NCT02434328Phase 3Completed

Efficacy and Safety of RTH258 Versus Aflibercept - Study 2

NCT00967850Phase 3Completed

Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia

NCT00599820Phase 3Terminated

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

NCT00406744Phase 3Terminated

Efficacy of Retreatments With Intravitreal Bevacizumab

NCT00417833Phase 2Terminated

Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

NCT06243406Not Yet RecruitingPrimary

Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization

NCT05662943Completed

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

NCT03024424Not ApplicableCompleted

Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD

NCT05494775Not ApplicableUnknown

Effect of Corona Virus on Intravitreal Injections

NCT04782271Phase 1Completed

Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops

NCT02015351Not ApplicableCompletedPrimary

Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study

NCT05055973UnknownPrimary

OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT.

Scroll to load more

Research Network

Activity Timeline